Literature DB >> 22157870

Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions.

David Feifel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22157870      PMCID： PMC3238071          DOI： 10.1038/npp.2011.184

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  5 in total

1.  Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin.

Authors:  Paul R Lee; Dana L Brady; Robert A Shapiro; Daniel M Dorsa; James I Koenig
Journal:  Neuropsychopharmacology       Date:  2005-10       Impact factor: 7.853

2.  Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.

Authors:  David Feifel; Kai Macdonald; Angel Nguyen; Patrice Cobb; Heather Warlan; Barbara Galangue; Arpi Minassian; Olga Becker; Jason Cooper; William Perry; Mischelle Lefebvre; James Gonzales; Allison Hadley
Journal:  Biol Psychiatry       Date:  2010-07-07       Impact factor: 13.382

3.  Peripheral oxytocin is associated with reduced symptom severity in schizophrenia.

Authors:  Leah H Rubin; C Sue Carter; Lauren Drogos; Hossein Pournajafi-Nazarloo; John A Sweeney; Pauline M Maki
Journal:  Schizophr Res       Date:  2010-10-13       Impact factor: 4.939

4.  Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating.

Authors:  D Feifel; T Reza
Journal:  Psychopharmacology (Berl)       Date:  1999-01       Impact factor: 4.530

Review 5.  The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans.

Authors:  Kai Macdonald; Tina Marie Macdonald
Journal:  Harv Rev Psychiatry       Date:  2010 Jan-Feb       Impact factor: 3.732
  5 in total
  8 in total

1.  Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Lauren L Drogos; S Kristian Hill; Anthony C Ruocco; Sarah K Keedy; James L Reilly; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; John A Sweeney
Journal:  Schizophr Bull       Date:  2014-03-11       Impact factor: 9.306

2.  A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes.

Authors:  Dongsheng Cai; Sudarshana Purkayastha
Journal:  Drug Discov Today Dis Mech       Date:  2013-06-01

3.  Oxytocin Receptor (OXTR) Methylation and Cognition in Psychotic Disorders.

Authors:  Tyler B Grove; Kyle J Burghardt; A Zarina Kraal; Ryan J Dougherty; Stephan F Taylor; Vicki L Ellingrod
Journal:  Mol Neuropsychiatry       Date:  2016-08-13

4.  Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis.

Authors:  Leah H Rubin; C Sue Carter; Jeffrey R Bishop; Hossein Pournajafi-Nazarloo; Margret S H Harris; Scot K Hill; James L Reilly; John A Sweeney
Journal:  Schizophr Res       Date:  2013-03-07       Impact factor: 4.939

5.  The effect of intranasal oxytocin treatment on conditioned fear extinction and recall in a healthy human sample.

Authors:  Dean Acheson; David Feifel; Sofieke de Wilde; Rebecca McKinney; James Lohr; Victoria Risbrough
Journal:  Psychopharmacology (Berl)       Date:  2013-05-05       Impact factor: 4.530

6.  Opposing effects of oxytocin on overt compliance and lasting changes to memory.

Authors:  Micah G Edelson; Maya Shemesh; Abraham Weizman; Shahak Yariv; Tali Sharot; Yadin Dudai
Journal:  Neuropsychopharmacology       Date:  2014-09-13       Impact factor: 7.853

Review 7.  Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease.

Authors:  Dasiel O Borroto-Escuela; Jens Carlsson; Patricia Ambrogini; Manuel Narváez; Karolina Wydra; Alexander O Tarakanov; Xiang Li; Carmelo Millón; Luca Ferraro; Riccardo Cuppini; Sergio Tanganelli; Fang Liu; Malgorzata Filip; Zaida Diaz-Cabiale; Kjell Fuxe
Journal:  Front Cell Neurosci       Date:  2017-02-21       Impact factor: 5.505

8.  Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models.

Authors:  Hai Zhang; Chenguang Wu; Qiaofen Chen; Xiaoluo Chen; Zhigang Xu; Jing Wu; Dongsheng Cai
Journal:  PLoS One       Date:  2013-05-20       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.